Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

464.13 +4.72 (+1.03%)
Streaming Delayed Price Updated: 9:53 AM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
62 63 Next >
3 Red-Hot Growth Stocks That Are Still Cheap Buys
It's not too late to invest in these great businesses. 
Via The Motley Fool
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
The Best Stocks to Invest $5,000 In Right Now
Today, the following three healthcare players look like fantastic bargains. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Sooner Rather Than Later
Now is the time to invest in these great stocks. 
Via The Motley Fool
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings
Via Benzinga
3 Monster Stocks to Buy Without Any Hesitation
These big stocks could become a lot bigger. 
Via The Motley Fool
The Latest Analyst Ratings for Vertex Pharmaceuticals
Via Benzinga
Is Vertex Pharmaceuticals Stock a Buy Now?
Jim Cramer recently hyped up one of the company's promising drugs. 
Via The Motley Fool
If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today
Via Benzinga
4 Ways to Grow $100,000 Into $1 Million for Retirement
Investing for big-time growth doesn't have to be risky. 
Via The Motley Fool
Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
3 Gene Editing Stocks to Generate Super-Charged Gains
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
The company can begin a pivotal study of its treatment for cardiomyopathy. 
Via Investor's Business Daily
The Stock Market Is Resilient But How Long Will It Last? Your Mid-October Update
We're continuing to see resilience in the US Stock Market in the headwinds of otherwise bearish or bad news, but is this the beginning of a larger rally or may the resiliency come to an end soon? 
Via Talk Markets
2 Top Biotech Stocks to Buy Right Now
Both companies are known innovators. 
Via The Motley Fool
Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy
Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (NASDAQ: CRSP) to Neutral from Ov 
Via Benzinga
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Healthcare Portfolio Focus Stocks
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields. 
Via Talk Markets
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
These two large-cap biopharma companies could have more room to run. 
Via The Motley Fool
This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street
This Wood favorite is heading for a big moment. 
Via The Motley Fool
2 Growth Stocks That Could Double Your Money, According to Wall Street
Find out why investment bank analysts are pounding the table on these stocks. 
Via The Motley Fool
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Friday Session
Via Investor Brand Network
3 Top Healthcare Stocks to Buy for October
These stocks have oodles of room left to run. 
Via The Motley Fool
Vertex to Announce Third Quarter 2023 Financial Results on November 6
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?
Wood has outperformed the market so far this year. 
Via The Motley Fool
Jim Cramer's Take on Vertex: Tackling Opioid Addiction with New Drug in Pipeline
CNBC's Jim Cramer has drawn investors' attention to Vertex Pharmaceuticals (NASDAQ: VRTX), a biotechnology company currently in the late stages of developing a non-opioid drug to treat acute pain.  
Via Benzinga
3 Biotech Stocks Ready to Break Out in 2024
These top three biotech companies are ready to roar into the new year with promising new trials, drugs, and innovative use of AI. 
Via InvestorPlace
3 No-Brainer Growth Stocks to Buy in October
The time is right to invest in these great stocks. 
Via The Motley Fool
Jim Cramer: This Company Is 'Arranging Deck Chairs On The Titanic... Not A Believer'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Topgolf Callaway Brands Corp. (NYSE: MODG) is making money. 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS